No Data
No Data
BioCryst Pharmaceuticals' ORLADEYO Recommended for Routine Prevention of Hereditary Angioedema in Portugal
Biocryst PharmaceuticalsS Ays Infarmed In Portugal Has Recommended ORLADEYO (Berotralstat) For The Routine Prevention Of Recurrent Attacks Of Hereditary Angioedema In Eligible Patients 12 Years And Older
Biocryst Pharmaceuticals Announces The Company Will Present Five Abstracts Featuring New Clinical And Real-World Outcomes With Oral, Once-Daily Orladeyo For The Prophylactic Treatment Of Hereditary Angioedema At The 2025 American Academy Of Allergy,...
BioCryst to Report Fourth Quarter 2024 Financial Results on February 24
Express News | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)